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Abstract
Establishing the neurological basis of behavioural dysfunction is key to provide a better understanding of Parkinson’s
disease (PD) and facilitate development of effective novel therapies. For this, the relationships between longitudinal
structural brain changes associated with motor behaviour were determined in a rat model of PD and validated by post-
mortem immunohistochemistry. Rats bearing a nigrostriatal lesion induced by infusion of the proteasome inhibitor
lactacystin into the left-medial forebrain bundle and saline-injected controls underwent magnetic resonance imaging (MRI)
at baseline (prior to surgery) and 1, 3 and 5 weeks post-surgery with concomitant motor assessments consisting of forelimb
grip strength, accelerating rotarod, and apormorphine-induced rotation. Lactacystin-injected rats developed early motor
deficits alongside decreased ipsilateral cortical volumes, specifically thinning of the primary motor (M1) and somatosensory
cortices and lateral ventricle hypertrophy (as determined by manual segmentation and deformation-based morphometry).
Although sustained, motor dysfunction and nigrostriatal damage were maximal by 1 week post-surgery. Additional volume
decreases in the ipsilateral ventral midbrain; corpus striatum and thalamus were only evident by week 3 and 5. Whilst
cortical MRI volume changes best predicted the degree of motor impairment, post-mortem tyrosine hydroxylase
immunoreactivity in the striatum was a better predictor of motor behaviour overall, with the notable exception of
performance in the accelerating rotarod, in which, M1 cortical thickness remained the best predictor. These results highlight
the importance of identifying extra-nigral regions of damage that impact on behavioural dysfunction from damage to the
nigrostriatal system.
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Introduction
Region-specific loss of dopaminergic neurons in the substantia
nigra pars compacta (SNc) is the pathological hallmark of
Parkinson’s disease (PD), a progressive neurodegenerative move-
ment disorder [1]. Neuronal loss is accompanied by formation of
intraneuronal inclusions, Lewy bodies, composed primarily of the
protein a-synuclein [2]. The anatomical and functional changes in
PD may be classified into a three phase model: (1) mesenchephalic
(dopaminergic neuronal loss), (2) basal ganglia (dopaminergic
deafferentation) and (3) cortical (functional reorganisation) [3].
Longitudinal investigations using structural magnetic resonance
imaging (MRI) provide a framework to map the sequence of
neuroanatomical changes at all levels of this model. This is an
advantage over techniques such as positron emission tomography
(PET), which can only focus on one level, for example pre-synaptic
dopamine terminals [4]. This information may then be related to
clinical symptoms in patients to identify their neuroanatomical
causes. This approach has been used successfully in several clinical
studies [3,5,6,7,8], but such studies are lacking in animal models.
MRI is well suited for this purpose, since the high anatomical
resolution permits collection of quantitative information on
morphological changes in the brains of disease models, which
may be directly correlated with behavioural phenotypes [9,10,11].
Notably, such studies in animal models offer a significant
advantage in that the neuropathology underlying MRI signal
changes may be investigated. Moreover, this approach has the
potential to identify surrogate markers of disease progression,
which may be beneficial in the evaluation of novel pre-clinical
models of PD and evaluation of experimental PD therapeutics
[9,10,12].
Although several MRI studies have been conducted in both
primate [13,14,15] and rodent models of PD [16,17,18,19,20,21],
these have primarily focussed exclusively on the nigrostriatal
system or on changes in brain function, rather than structure.
Previously, we have identified in vivo a pattern of morphological
changes in several brain regions in rats lesioned by intranigral
injection of the proteasome inhibitor lactacystin, which were
associated with behavioural impairment in this model [11].
Intracranial injection of proteasome inhibitors into the nigrostri-
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including a-synuclein aggregation [11,22,23,24,25]. However,
whilst dopaminergic neurons may be preferentially sensitive to
proteasome inhibition [26], synthetic proteasome inhibitors may
also induce non-specific neuronal toxicity [27,28] and affect
astrocyte proliferation and morphology [29,30]. Thus, the aim of
the current study was to map the evolution of neurodegenerative
changes (primary and secondary) in the lactacystin model and
examine their relevance to behavioural dysfunction using a
combination of MRI, behavioural assessment and linear regression
analysis. Post-mortem analyses of the brain were also conducted to
identify potential neurobiological substrate(s) underlying in vivo
morphometric changes. We hypothesized that structural brain
changes in the extra-nigral regions, as well as the nigrostriatal
system, underlie motor behavioural impairment in vivo.
Materials and Methods
Experimental animals
Male Sprague-Dawley rats (250610g, Harlan, UK) were
housed in groups of three at 2161uC on a 12 hr light: dark cycle
(lights on 0700, lights off 1900). Standard rat chow and drinking
water were available ad libitum. All animal experiments were
carried out in accordance with the Home Office Animals
(Scientific procedures) Act, UK, 1986 and were approved by the
Kings College London ethical review panel (Designation no. PCD
70/2901.)
Experimental design
The experimental design for this study is shown in Figure 1.
Animals were randomly assigned to either control or lesion groups
using a random number sequence (lesion N=8; control N=7). All
animals underwent serial evaluation of brain structure by MRI and
motor behavioural testing at baseline prior to surgery and 1, 3 and 5
weeks (wks) post-surgery (Figure 1). Drug-induced rotation as an
index of nigrostriatal damage was assessed at 1, 3 and 5 wks post-
surgery. All animals underwent post-mortem histological assessment.
Two separate cohorts of animalswere alsolesioned with lactacystin or
saline, but sacrificed at 1 or 3 wks post-lesion respectively. These
animals were included for comparative analysis of post-mortem
neuropathological changes at these time-points to investigate the
pathology underlying MRI signal changes at 1 and 3 wks in vivo.
Induction of nigrostriatal lesions
Nigrostriatal lesions were induced as previously described, with
saline and lactacystin designated animals operated on in a
randomised fashion in the same surgical session. [11]. Briefly,
animals were anaesthetised by i.p. injection of a mixture of
medetomidine hydrochloride (DomitorH, 0.25 mg/kg) and keta-
mine hydrochloride (Vetalar
TM, 230 mg/kg) and positioned in a
stereotaxic frame (Kopf Instruments, Tujunga, CA, USA).
Animals assigned to the lesion group received a unilateral injection
of lactacystin (10 mg in 2.5 ml; L6785, Sigma-Aldrich, Poole, UK)
into the L-MFB (AP: 24.4 mm, ML: 21.5 mm lateral from
bregma and 27.8 mm ventral to dura) [31]. Lactacystin was
dissolved in 0.9% saline (pH 7.4) immediately prior to use and
stored on ice to prevent degradation. Injections were performed at
a rate of 1 ml/min using a motorized syringe pump and the needle
was slowly withdrawn 5 min after lesioning to minimize diffusion
of toxin into the injection tract. Anesthesia was reversed 1 hr after
induction by subcutaneous (s.c.) injection of atipamezole hydro-
chloride (AntisedanH, 5 mg/kg). Animals assigned to the control
group underwent identical surgery, but received an injection of
0.9% saline. Post-operative care included analgesia (buphrenor-
phine, 0.3 mg/kg s.c. during the first 48 hr), fluid-replacement
(4 ml glucosaline solution i.p.) and mashed high-nutrient food
pellets during the first week after surgery. Animals were weighed
and semi-quantitatively scored daily for neurological deficits using
a general neurological rating scale [32]. This was done daily in a
blinded fashion until the end of the experiment.
Behavioural testing
Prior to testing (training or trial) animals were acclimatized to
the testing room for 30 min.
Grip strength meter test. Forelimb motor dysfunction was
assessed using a grip strength meter (GSM; TSE Systems, Bad
Homburg, GER) as previously described [11,33].
Accelerating rotarod. Performance on the accelerating
rotarod test (TSE systems, Bad Homburg, GER) was assessed as
previously described, with modification [34]. Briefly, animals were
assessed pre-operatively at five speeds of rotation: 8, 10, 12, 14 and
16 rpm to establish a baseline performance. Animals were allowed
to remain stationary at 0 rpm for 10 sec, after which the speed was
increased to 8 rpm for 10 sec and then progressively to 10, 12 and
14 rpm for 10 sec each. The highest speed, 16 rpm, was
Figure 1. Experimental design and time-points for MRI and behavioural analysis in animals undergoing longitudinal examination.
Additional cohorts of lesioned and control animals were sacrificed at weeks 1 and 3, respectively, for histological analysis.
doi:10.1371/journal.pone.0017269.g001
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rotational speeds were chosen so that sham (uninjured) animals
would not fall off during the test. A rat was considered failing the
4-min period test if (a) it fell off the device before the time period
elapsed or (b) it simply gripped the rungs and spun for two
consecutive revolutions rather than actively walking on the
rotating rods. Rats from both groups were tested twice daily
(once each morning and afternoon) over a 3-day period at 1, 3 and
5 wks post-surgery. The means of the test results were used for
statistical analysis.
Rotational asymmetry. Apomorphine-induced rotation
(0.1mg/kg) as an index of nigrostriatal damage was evaluated in
a bank of eight rotameter bowls as previously described [11,35].
Lesioned animals that did not reach a cut-off value of .5
contralateral turns, per minute, (indicative of ,70% nigral cell
loss) were excluded from further analysis.
Magnetic resonance imaging
In vivo T2-weighted (T2W) MR images were acquired using a
7.0 T horizontal small bore magnet (Varian, Palo Alto, CA, USA)
with a custom built head RF coil (David Herlihy, Imperial College
London) linked to a LINUX-based control console running VnmrJ
acquisition software (v2.3, Varian, Palo Alto CA, USA), using a
multi-echo, multi-slice spin-echo pulse sequence (MEMS), with the
following scan parameters: FOV=35 mm635 mm; matrix=
1926192; TR=4200 ms; TE=10, 20, 30, 40, 50, 60, 70,
80 ms; 4 averages, total scan duration 54 minutes, as previously
described [11]. Fifty contiguous 500 mm-thick coronal slices were
acquired ensuring complete coverage of the brain. Post-acquisi-
tion, MR images were visually inspected for motion or intensity
artefacts and scans displaying such were excluded. On this basis,
the final N numbers for MR image analysis at each time-point
were lactacystin N=7 and saline N=5. All echo times (10–80 ms)
were summed and converted to ANALYSE 7.5 (Mayo Clinic,
Rochester, USA). Quantitative T2 relaxation maps were also
obtained by a mono-exponential fit of the eight multi-echo images
(TE=10–80ms) using VnmrJ software [11].
MR image analysis
Signal intensity measurements. Signal intensity (SI) values
for T2 were measured in both the contralateral and ipsilateral
hemispheres of saline and lactacystin-lesioned animals, in the
corpus striatum (STR) and the substantia nigra (SN) from
quantitative T2 maps as previously described [11].
Manual segmentation volumetric analysis. The volume
of the whole brain (WBV), ventral midbrain (VM), corpus striatum
(STR), cerebral cortex (CTX), hippocampus (HPC), cerebellum
(CB) and lateral ventricles (LV), were measured using a manual
segmentation approach [36], as described in our previous study
[11]. Thickness of the primary motor cortex (M1) and the barrel
field of the primary somatosensory cortex (S1BF) were also
measured on in vivo MR images, as previously described [37,38].
Deformation based morphometry. A single baseline scan
from a control animal was chosen, based on scan-quality, as a
canonical reference (CR), which defines an anatomical space for
analysis. The orientation of the CR was further standardised (sCR)
by rigidly registering the x-axis mirror (mCR) to the original CR
and applying the halfway transformation. An approximate brain-
region for registration was created on the sCR using the 3D
region-growing tools available in MRIcroN (MRIcroN: http://
www.sph.sc.edu/comd/rorden/MRicron/). The brain mask was
dilated outside the brain boundary and foreground: background
voxels were weighted 1000:1. All scans were normalised to the
sCR using FLIRT registration [39,40] with 9 degrees of freedom
(dof) and the –nosearch option followed by transformation into the
sCR space. All scans were corrected for intensity inhomogeneity
artefact using N3 [41]. High signal-to-noise mean images for each
group (control, lesion) at each time-point (baseline, 1, 3 and 5 wks)
were created by averaging the relevant registered intensity-
corrected images. High-dimensional fluid-registration [42] was
used to warp each lesion-mean to the normal-mean at the
corresponding time-point; this approach removes growth-related
confounds by comparing each time-point against an age-matched
control. Maps of localised inter-group volume differences were
computed from the Jacobian determinant of the non-rigid
transformation at each time-point. Relative differences in global
volumetric scaling between groups computed from the 9-dof
registration were combined with Jacobian results to produce maps
of total average volume-difference between groups.
Tissue collection
Animals were terminally anaesthetised by a sodium pentobar-
bital overdose (60 mg/kg i.p.) and transcardially perfused with
0.9% saline, followed by ice-cold 4% paraformaldehyde (PFA) in
0.2 M phosphate buffer, pH 7.4. Brains were rapidly dissected
out, post-fixed for 24 hours and cryo-protected in buffered 30%
sucrose. Serial coronal sections (40 mm) were cut on a freezing
microtome at 220uC and stored in cryoprotective solution
containing 0.05% sodium azide at 220uC until processed for
immunohistochemistry.
Immunohistochemistry
Tissue sections processed for stereology were immunostained
free floating using a standard immunoperoxidase method as
described previously [11]. To identify dopaminergic neurons in
the SNc and fibres in the striatum, sections were stained with
rabbit anti-tyrosine hydroxylase (TH, AB151, Chemicon, 1:3000).
To examine global neuronal loss, tissue sections were stained with
mouse anti-Neuron specific nuclear protein (NeuN, MAB377,
Chemicon, 1:1000).
To visualize a-synuclein aggregation in dopaminergic neurons,
tissue sections were processed for fluorescence microscopy.
Sections were rinsed 3610 min with PBS, followed by 1 hr
incubation in blocking solution (10% normal goat serum, 0.3%
Triton X-100 in PBS) at room temperature (RT). Sections were
double-labelled with mouse anti-a-synuclein (610786, BD Biosci-
ences, 1:100) and rabbit anti-tyrosine hydroxylase (TH, AB151,
Chemicon, 1:3000). All primary and secondary antibodies were
diluted in blocking solution. All incubations with primary
antibodies were overnight at 4uC, followed by incubation with
appropriate secondary antibodies conjugated to a fluorescent
moiety for 2 hr at RT (ALEXA488 1:500, ALEXA555 1:1000; all
from Molecular Probes, Invitrogen, UK). Tissue sections were
washed thoroughly in PBS and mounted in vectashield containing
49, 6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, UK)
on glass slides. Antibody specificity was confirmed in adjacent
tissue sections with the primary or secondary antibody omitted.
Post-mortem histological analysis
Quantification of neuronal loss in the SNc and striatum
using the optical fractionator probe. Unbiased estimates of
the number of TH-positive (TH+) neurons within the SNc in
saline and lactacystin-lesioned animals were obtained as previously
described [11]. To obtain unbiased estimates of the total number
of neurons in the striatum in each group, the optical fractionator
probe was utilized. The number of NeuN-positive cells were
counted in every 12
th serial section of the striatum with the
reference volume defined from +2.2 mm to 21.4 mm from
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at62.5 magnification and Cavalieri’s method was used to estimate
the volume of the reference region [44,45]. These values were
compared to MRI-derived measurements of striatal volume to
check the reproducibility of these in vivo measurements. The
number of neurons was sampled in each tissue section using
counting frames (80680 mm), systematically distributed with
known x and y steps throughout the region from a random
starting point. At least 20–25 counting frames were sampled per
section, under 660 magnification. Cells were only counted if they
did not touch the exclusion lines and if they came into focus within
the 18-mm thick optical dissector, with 2-mm guard zones.
Estimates of neuronal number were generated by Stereo
Investigator software. The coefficients of error (CE) were
calculated according to the procedure of West and colleagues
with values ,0.10 accepted [46]. To ensure the absence of bias in
cell counting, slides were coded such that the operator was blinded
to the surgical status of the animal.
Post-mortem cortical thickness measurements. To
replicate MRI measurements post-mortem, the thickness of the
M1 and S1BF were measured using the contour measurement tool
in Stereo Investigator software using the same microscope set-up
described for stereology analysis. M1 thickness was measured
2 mm lateral from midline, on every 12
th serial section, at slices
corresponding approximately to +3.00 mm, +2.52 mm and
+2.04 mm from the cingulum to the brain surface. S1BF
thickness was measured 6 mm from midline on every 12
th serial
section corresponding approximately to Bregma 20.36 mm,
20.84 mm and 21.32 mm from the external capsule to the
brain surface. The mean thickness of M1 and S1BF cortices was
calculated for each subject from the average of ten lines drawn per
structure. The mean values for each subject, in each hemisphere
were then averaged to give an overall group mean.
Optical density measurements. Optical density of TH+
fibres in the corpus striatum was measured as previously described
with modification [11,47].
Statistical analysis
All data are expressed as the mean 6 SEM. Behavioural data,
MRI volumes and T2 SI measurements were analysed using
repeated measures (RM) two-way analysis of variance (ANOVA)
with lesion and time as main effects. Post-hoc tests were performed
using Bonferroni’s correction for multiple comparisons. Post-
mortem data were analysed using two-tailed students t-test.
Correlations between regional brain volume changes, histology
and motor behaviour across time were evaluated for all subjects
(both saline controls and lactacystin-lesioned animals) using linear
multiple regression models (variables entered) or a Pearson’s
correlation, as appropriate. All statistical analysis was performed in
SPSS (v17.0; SPSS Inc. Woking; UK).
Results
Lactacystin microinjecton induces motor behaviour
deficits
Lesioned animals, but not saline controls, consistently showed
deficits in spontaneous motility, possibly reflecting developing
bradykinesia in these animals. A clear ipsiversive deviated
posture with spontaneous circling and dystonic deviation of the
body axis towards the ipsilateral site of injection was also
observed in lesioned animals, but not saline-controls. This was
reflected in an overall increase in median neurological score,
up to day 14, after which neurological dysfunction remained
unchanged (Figure S1).
Forepaw grip strength improved with time in saline controls
[F(3,30)=13.49, p,0.0001, Figure 2A]. By contrast, in lesioned
animals [F(1,36)=19.95, p,0.001, Figure 2B], there was a
significant impairment in grip strength of the contralateral forepaw
by wk 1 (p,0.05), which was maintained at wk 3 (p,0.01) and wk
5( p,0.01). As there was no significant difference in forepaw grip
strength prior to the administration of lactacystin (i.e. baseline),
grip strength in both forepaws evolved differently over time
(F(3,36)=11.79, p,0.001). Forepaw grip strength was therefore
significantly affected by administration of lactacystin into the L-
MFB by week 1, but did not exhibit a progressive worsening of this
deficit.
Performance on the accelerating rotarod revealed a significant
impairment of lesioned animals (F1,36=17.48; p,0.0001,
Figure 2C). However, this deficit was only evident after baseline
(F(3,36)=7.769, p,0.01), although both groups’ performance
changed with time (F3,36=9.79; p,0.0001). Lesioned animals
showed a significantly shorter latency to fall compared to saline-
controls at wk 1 (p,0.001), wk 3 (p,0.01) and wk 5 (p,0.01). By
wk 3 and 5, lesioned animals performance appeared to slightly
recover, although it remained significantly impaired compared to
saline controls throughout. Thus, motor co-ordination impairment
was greatest at wk 1.
To probe striatal dopamine availability, animals were chal-
lenged with the dopamine D2 receptor agonist apomorphine.
Lesioned animals exhibited a significant increase in contraversive
rotations (F1,26=159.0; p,0.0001) at all time-points tested
(p,0.01; Figure 2D). On average, lesioned animals displayed net
contraversive turns of 6–7 turns/min, with locomotor activity
increasing steadily after 5 min of drug administration and
maintained for approximately 35 minutes, at which point
locomotor activity decreased back to baseline. One lesioned
animal did not demonstrate significant (.5 turns/min) contralat-
eral circling and was thus excluded from all further analysis.
Additional lesioned animals, but not saline controls, sacrificed at
wk 1 and wk 3 showed identical rotational behaviour (data not
shown).
Substantia nigra signal intensity evolves longitudinally
following microinjection of lactacystin
To probe the underlying pathology responsible for inducing this
behavioural phenotype, longitudinal T2-weighted MR images
were acquired to measure the evolution of structural deformations,
as well as changes in signal intensity that indicate a change in
tissue composition. Remarkable changes in the contrast of the
MR images were observed in the ventral midbrain across time
in lesioned animals, which were absent in saline controls
(Figure 3A, B). A hyperintense signal in an area approximate to
the SN was present at wk 1 post-lesion, which evolved into an area
of hypointense signal at later time-points. Quantification revealed
longitudinal changes in the ratio of T2 SI between the ipsilateral
and contralateral hemispheres, in the SN (F(1,30)=5.87; p,0.05,
Figure 3C). This SI evolution in lactacystin animals was only
present post-lesion (F(1,30)=7.39; p,0.01), but there was no overall
effect of time (F(1,30)=5.36; p.0.05) indicating that the signal
change was not associated with normal aging. The hyperintense
contrast in the SN of lesioned animals at wk 1 post-lesion,
however, failed to reach statistical significance. By contrast, at later
time-points, the T2 SI ratio was significantly reduced (hypointense
contrast) in the SN of lesioned animals at wk 3 (p,0.05) and wk 5
(p,0.05). No significant alterations in T2 SI ratio were observed in
the STR at any-time point, in either lesioned animals or saline
controls (Figure 3D). Specific changes in T2 SI are therefore only
observed in the SN in this model, suggesting that these reflect
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characteristics of this region.
Microinjection of lactacystin produces a progressive
pattern of brain structural changes
Visual inspection of MR images revealed a progressive
enlargement of the lateral ventricles (LV), accompanied by
conspicuous atrophy in the ventral midbrain (VM) and ventral
thalamus, with a concomitant increase in cerebrospinal fluid (CSF)
space in the lesioned group that was absent in saline controls
(Figure 3A, B). Longitudinal changes in brain volume for major
brain structures in saline and lesioned animals were investigated
utilising a manual segmentation analysis of in vivo MR images (see
Table S1 for summary of statistical analyses).
Lactacystin microinjection into the L-MFB induced signifi-
cant gross morphological changes that affected whole brain
volume (WBV) compared to saline controls at wk 3 (p,0.05) and
wk 5 (p,0.05), but not wk 1 (Figure S2A). These changes were
contained within the cerebrum as no significant change in the
volume of the cerebellum over time was observed (Figure S2B).
For sub-cortical brain regions, a significant volume decrease in
the ipsilateral ventral midbrain (VM) appeared from wk 3
onwards, increasing by wk 5, suggesting a progressive degen-
eration of this structure in lesioned animals. A significant
volume decrease was observed in the ipsilateral STR from Wk 3
onwards in lesioned animals compared to saline controls
(Figure 4A, B). A trend towards a decreased ipsilateral STR
volume was observed at wk 1, but this failed to reach statistical
significance (Figure 4B).
Volume changes were not confined to the basal ganglia
following lactacystin microinjection. Significant hypertrophy of
the ipsilateral LV was observed in lesioned animals at all post-
lesion time points (p,0.01; Figure 4C). A trend towards
hypertrophy of the contralateral LV of lesioned animals was also
observed, but this failed to reach statistical significance (Figure 4C).
Additionally, a significant reduction in the volume of the ipsilateral
cerebral cortex (CTX) was observed at wk 1 (p,0.05) in lesioned
animals compared to saline controls. This increased further at wk
3( p,0.01) and wk 5 (p,0.01; Figure 4E). Within the CTX,
lesioned animals had significantly thinner M1 and S1BF compared
to saline controls at wk 1 (p,0.05), wk 3 (p,0.01) and wk 5
(p,0.01, Figure 4F, G). No significant changes were observed in
the thickness of either the M1 or S1BF in the contralateral
hemisphere in either treatment group (Figure 4F, G). However, no
significant volume change was observed in the hippocampal
formation in either hemisphere in either saline or lesioned animals
(Figure 4D).
To examine the relationship between unspecific whole brain
volume decreases and specific regional volume changes, MRI
volume measurements (saline and lactacystin) for the ipsilateral
Figure 2. Parkinsonian-like motor phenotype in Lactacystin-lesioned animals. (A) Saline-injected controls show no deficits in the GSM test
for either limb at any time-point. (B) Lesioned animals develop a progressive impairment in the grip strength of the contralateral forelimb in the GSM
test. Data shown in (A, B) are mean grip force (G) 6 SEM. **p,0.01 contralateral limb vs. ipsilateral limb. (C) Lesioned animals, but not saline controls
show motor co-ordination deficits as evidenced by shortened latency to fall in the accelerating rotarod test at all time-points post-surgery. Data
shown are mean latency to fall (sec) 6 SEM. *p,0.05; **p,0.01; saline vs. lactacystin-injected. (D) Lactacystin-lesioning induces significant
contralateral circling in response to apomorphine challenge (0.1 mg/kg s.c.) at all time-points post-surgery. Data shown are mean net contraversive
rotations 6 SEM. ***p,0.001; saline (N=5) vs. lactacystin-injected (N=7).
doi:10.1371/journal.pone.0017269.g002
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analysis (Table 1). This revealed a highly significant positive
correlation between ipsilateral CTX volume alone and WBV at
wk 1. By wk 3, both the ipsilateral VM and ipsilateral STR volume
in addition to ipsilateral CTX volume were associated with
changes in WBV. Notably, decreases in WBV only reached
statistical significance from wk 3, indicating that tissue volume
decrease in the CTX alone at wk 1 is insufficient to induce a
change in WBV in lactacystin-lesioned animals, but that changes
in multiple brain structures are required. By contrast, ipsilateral
LV volume was negatively correlated with WBV, indicating that as
WBV shrinks, ventricular volume increases. At wk 5, only
ipsilateral VM volume was significantly correlated to WBV,
implying that a progressive degeneration of the ipsilateral VM is
primarily influencing changes in WBV at this stage of degener-
ation, but no other region.
To examine whether these MRI changes are related to
behavioural impairment in this model, equation models were
derived using a multiple linear regression to predict final
behavioural impairments based on MRI measurements (Table 2).
Overall, thickness of the ipsilateral CTX was revealed as the best
predictor of forepaw grip strength, whilst M1 cortex thickness best
predicted performance on the accelerating rotarod. Unexpectedly,
ipsilateral LV volume best predicted the number of contraversive
rotations after apomorphine administration. Neither ipsilateral
STR volume, nor ipsilateral VM volume, were significant
predictors of behavioural outcome for any behavioural test
performed.
Figure 3. Representative longitudinal in vivo T2W MR images acquired from (A) saline-injected controls and (B) lactacystin-lesioned
animals. MR images are shown at four coronal levels (approximate distances from bregma are shown in mm). Note the absence of visible
pathological changes in saline injected controls. By contrast, in lesioned animals hypertrophy of the lateral ventricles and deformation of the ventral
midbrain with concomitant increase in CSF space (dashed arrows in B) may be observed post-lesion. Apparent contrast changes were also present in
the area of the substantia nigra (solid arrows in B) with time. (C) No significant alteration in T2 signal intensity was observed at any time-point
between groups in the striatum. (D) By contrast, a clear temporal evolution of changes in T2 signal intensity are apparent in the substantia nigra of
lactacystin-lesioned animals compared to saline controls, ranging from hyperintense signal at wk 1 to hypointense signal at wk 3 and wk 5. Data
shown are the mean ratio of T2 signal intensity between the contralateral non-injected and ipsilateral injected brain hemispheres in each group 6
SEM. *p,0.05; saline (N=5) vs. lactacystin (N=7).
doi:10.1371/journal.pone.0017269.g003
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This analysis identified several areas of local tissue volume
change in cortical and sub-cortical areas, which evolved with time
(Figure 5). At wk 1, increases in CSF space in lactacystin-treated
animals are evident and persist until wk 5. At wk 3, local volume
decreases in the ipsilateral VM were evident and continued to
expand at wk 5. Similarly, volume decreases were observed in the
ipsilateral STR at wk 3 and 5, but interestingly, DBM analysis
suggests that volume change is confined to the lateral and medial
dorsal regions of the ipsilateral STR. Decreases in the ipsilateral
CTX volume were not readily apparent from wk 1 onwards, but
small, localized areas of volume decrease may be observed in
frontal cortical areas. By wk 3 and wk 5 however, cortical volume
decreases are widespread in the ipsilateral hemisphere. Intrigu-
ingly, DBM analysis also suggests volume decreases in the
contralateral CTX by wk 5. No local tissue volume changes were
observed in the hippocampus. Apparent changes in the cerebellum
were a reflection of the general brain volume decrease that
resulted in a larger gap between cerebrum and cerebellum. Taken
together, DBM analysis confirms the manual segmentation results.
Notably, DBM identified additional local tissue volume changes
in areas of the brain that were immeasurable using the manual
segmentation approach. For instance, clear volume decreases were
observed in the ipsilateral ventral thalamus and globus pallidus
from wk 3 onwards (Figure 5). Volume decreases were also
observed in other ipsilateral cortical regions from wk 3 onwards,
including areas approximate to the piriform and lateral entorhinal
CTX (Figure 5). DBM detected additional significant expansion of
tissue volume in an area approximate to the SN at wk 1, which was
replaced by decreases at wk 3 and wk 5.
In vivo MRI atrophy reflects post-mortem
histopathological changes
To confirm in vivo MRI measurements, the volume of the STR
was determined post-mortem by stereology using the Cavalieri
probe estimator, which confirmed a significant decrease in the
volume of the ipsilateral STR in lesioned animals, compared to
saline controls (p,0.0001; Figure 6A). No significant change was
observed in the contralateral STR in either group (Figure 6A).
Overall, there was excellent correspondence between in vivo MRI
and post-mortem histological measurements of STR volume
(r=.879; p,0.001; Figure 6B). Similarly, cortical thinning in the
M1 and S1BF CTX measured from MR images was confirmed
post-mortem in the M1 (p,0.01) and S1BF (p,0.01) (Figure 6C).
No change was observed in the contralateral hemisphere in either
group. Good correspondence was observed between in vivo MRI
and post-mortem cortical thickness measurements for both M1
(r=.646; p,0.05) and S1BF (r=.691; p,0.05; Figure 6D).
Neuropathology underlying tissue volume changes
To identify the specific neural substrates of structural changes,
animals evaluated by serial MRI underwent post-mortem
immunohistochemical evaluation of the integrity of the nigrostri-
atal system. At the level of the STR, lactacystin microinjection into
the L-MFB resulted in a ,70% reduction of TH+ fibres in the
ipsilateral STR 5 wks post-surgery, accompanied by a visible
hypertrophy of the LV, relative to the intact contralateral
hemisphere. These changes were not observed in saline controls
(p,0.001; Figure 7A, B). To establish whether volume change in
the ipsilateral STR at Wk 5 reflects atrophy due to neuronal loss,
the number of NeuN+ cells in the contralateral and ipsilateral
striatum was quantified. This confirmed no significant difference
in the number of NeuN+ cells in the ipsilateral striatum relative to
the contralateral striatum in either saline or lactacystin-injected
animals (Figure 7C, D). A significant increase in neuronal density
(NeuN+ cells/mm
3) in the ipsilateral striatum of lactacystin
lesioned animals was observed (49,37762771 vs. 41,26061961
neurons/mm
3; p,0.05), which was absent in saline controls
(43,30961925 vs. 41,80461693 neurons/mm
3; p.0.05). Taken
together these data suggest striatal volume change in this model
does not reflect neuronal loss per se.
At the level of the SNc, lactacystin microinjection into the L-
MFB resulted in a substantial loss of TH+ cells in the ipsilateral
SNc, but also the VTA, relative to the intact contralateral
hemisphere at wk 5, which was not observed in saline controls
(Figure 7E). Quantification by stereology confirmed a significant
Table 1. Correlations between in vivo whole brain volume
and regional brain volume changes across time.
Brain region
WBV
(wk 1)
WBV
(wk 3)
WBV
(wk 5)
Ventral midbrain .196 .815** .688*
Corpus striatum .412 .786** .538
Cerebral cortex .712** .680*. 525
Lateral ventricles 2.322 2.593* 2.287
M1 cortex .530 .495 .273
S1BF cortex .431 .384 .012
*Correlation is significant at the 0.05 level,
**correlation is significant at the 0.01 level. (Abbreviations: WBV, whole brain volume).
doi:10.1371/journal.pone.0017269.t001
Table 2. Multiple regression analysis between MRI and
behavioural data.
Behavioural test Equation model predicting behaviour at wk 5
GSM test =2921.63+(.914*CTX volume)
Accelerating rotarod =2539.38+(.826*M1 cortex thickness)
Apomorphine rotation =256.66+(.846*LV volume)
(Abbreviations: CTX, cortex; M1, primary motor cortex; LV, lateral ventricle).
doi:10.1371/journal.pone.0017269.t002
Figure 4. Time-course of regional brain volumetric changes in saline and lactacystin-injected animals. Significant tissue volume change
was observed in (A) the ipsilateral ventral midbrain and (B) ipsilateral corpus striatum at 3 and 5 wks post-surgery compared to the non-injected
contralateral hemisphere and both brain hemispheres in saline controls. (C) Lateral ventricle hypertrophy and (D) cortical atrophy were present from
1-wk post-surgery and maintained at 3 and 5 wks in lesioned animals, but not saline controls. (E) No significant change in the volume of the
hippocampus was observed in either hemisphere in either group at any time-point. Significant thinning of the primary motor (F) and primary
somatosensory cortex were also present from wk 1 post-lesion in lactacystin-injected animals, but not saline controls. Data shown are mean volume
(mm
3 A–E) or thickness (mm, F, G) 6 SEM. ***p,0.001 ipsilateral hemisphere vs. non-injected contralateral hemisphere in lactacystin-injected
animals; wwwp,0.001 ipsilateral hemisphere of lactacystin-lesioned animals vs. ipsilateral hemisphere of saline controls. Saline, N=5, lactacystin,
N=7.
doi:10.1371/journal.pone.0017269.g004
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animals relative to the intact contralateral hemisphere (p,0.0001;
Figure 7F). No loss of TH+ cells was observed in either hemisphere
of the SNc in saline controls (Figure 7F). Loss of nigral TH+
neurons was accompanied by a distinct pattern of a-syn
aggregation in the SNc. Large irregular a-syn inclusions were
observed in a low proportion of the rare surviving TH+ cells in the
SNc at wk 5. Surviving TH+/a-syn- cells were also present, as
were TH-negative cells that contained a-syn aggregates. Free
aggregates of a-syn were also observed in the parenchyma. No a-
synuclein (a-syn) aggregation was observed in saline-injected
controls (Figure 7G).
To document the time-course of pathological changes in the
nigrostriatal system, post-mortem immunohistochemical analysis
was carried out in additional cohorts of lesioned and control
animals, sacrificed at 1 and 3 wks post-surgery respectively. This
revealed that in lesioned animals TH+ fibre loss in the ipsilateral
STR, TH+ cell loss and the pattern of a-syn aggregation in the
ipsilateral SNc was directly comparable at wk 1 and wk 3, to that
observed at wk 5 (Figure S3).
Lactacystin microinjection induces secondary
neurodegeneration in the thalamus and ventral midbrain
To determine if volume changes in other brain regions are the
result of secondary neurodegeneration following the primary insult
caused by nigrostriatal destruction, the presence or absence of
neuronal loss in the M1 cortex, thalamus, and ventral midbrain
were assessed qualitatively from NeuN-stained tissue sections
(Figure 8). No evidence of gross neuronal loss was observed in the
M1 cortex (Figure 8A) or the S1BF (data not shown), in either saline
controls or lesioned animals, at wk 5 (Figure 8A) nor at wk 1
(Figure S4) or wk 3 post-lesion (Figure S5). By contrast, in lesioned
animals, but not saline controls, severe neuronal loss was observed
in the ipsilateral ventral posterolateral (VPL) and ventral
posteromedial (VPM) thalamic nuclei at wk 5 (Figure 8B).
Similarly, in the ipsilateral ventral midbrain (VM) of lesioned
animals, but not saline controls, extensive neuronal loss was
observed in numerous nuclei including the red nucleus (RN),
medial genticulate nucleus (MGN) and anterior pretectal nucleus
(APTD) at wk 5 (Figure 8C). Extensive neuronal loss was also
observed in the SNc at this time-point (Figure 8D). Additionally,
the substantia nigra pars reticulata (SNpr) and the ventral
tegmental area (VTA) were not free from the toxicity of lactacystin
at wk 5 (Figure 8D). Analysis of lesioned animals sacrificed at wk 1
and wk 3 post-lesion revealed that neuronal loss in the thalamus
and ventral midbrain was absent at wk 1 (Figure S4), but present at
wk 3 post-lesion (Figure S5). These data are consistent with the
evolution of substantial volume decreases identified by manual
segmentation and DBM in the thalamus and ventral midbrain.
Correlation analyses between brain volume change,
behavioural dysfunction and post-mortem
neuropathology
To identify whether MRI changes are associated with
underlying nigral pathology, correlation analyses were performed
between in vivo MRI measurements and post-mortem neuropa-
thology measurements obtained at wk 5. Multiple regression
analyses were also performed to identify which if any, in vivo MRI
measurement best predicted nigrostriatal damage. Loss of both
ipsilateral striatal TH+ fibres and nigral TH+ cells was
significantly correlated with volume changes in the ipsilateral
VM, STR, CTX, LV and M1 cortex thickness, but not S1BF
cortex thickness or SI T2 measurements in the SN at this time-
point (Table 3). Multiple regression analysis identified ipsilateral
Figure 5. Deformation Based Morphometry confirms and extends manual segmentation analysis. Comparisons between the saline and
lactacystin mean normalised MR images are shown for each time-point (p,0.02 uncorrected). The coloured overlay shows the scale factor of local
apparent volume differences (on a logarithmic scale). Red/yellow indicates local tissue volume expansions, whilst blue/cyan indicates local tissue
volume contractions.
doi:10.1371/journal.pone.0017269.g005
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whilst VM volume was the best predictor of TH+ fibre density at
wk 5 (Table 4).
Correlation analysis between nigrostriatal pathology and
behavioural phenotype at wk 5 were also performed (Table 5).
Highly significant correlations were found between loss of
ipsilateral striatal TH+ fibres and nigral TH+ cells, as well as
behavioural impairment in this model (Table 5). Multiple
regression analysis confirmed that TH+ fibre density in the STR
was the best predictor of behavioural impairment for all tests
(Table 6). Multiple regression analyses determined which mea-
surements, in vivo MRI or post-mortem histology, best predicted
behavioural impairment in this model (Table 6). Interestingly, for
both grip strength and apomorphine rotation, TH+ fibre density
(post-mortem) was the strongest predictor over any MRI
measurement. However, for performance in the accelerating
rotarod, M1 cortical thickness as measured from MR images
remained the best overall predictor of performance.
Discussion
Establishing the neurological basis of behavioural dysfunction is
key to provide a better understanding of PD. To this end, using a
combination of in vivo MRI and behavioural testing, we have
identified the spatiotemporal sequence of tissue volume and signal
intensity (SI) changes in animals lesioned with the proteasome
inhibitor lactacystin, a rat pre-clinical model of PD, many of which
have been reported from clinical neuroimaging studies of PD
patients. Our manual analysis of brain volume changes is
complemented by the application of deformation-based mor-
phometry (DBM), which revealed additional pathology in lesioned
animals, particularly in the thalamus, also reported in PD patients
[48]. Using multiple regression analysis, we have established which
in vivo MRI-based structural changes predict behavioural dysfunc-
tion. Consistent with our hypothesis, pathological changes in the
basal ganglia, as well as extra-nigral structural alterations,
particularly in the cortex, predict motor deficits in this model.
Sequence of behavioural and neuropathological changes
Lactacystin lesioning resulted in significant motor impairments,
consistent with previous reports in this model [11,22,23,24,25].
Notably, inallthree tests,functional impairment inlesioned animals
was maximal by wk 1 post-lesion. Interestingly, in the rotarod test,
lesioned animals performance improved slightly by weeks 3 and 5
post-lesion.Thismay reflectlearning of the test paradigmor may be
related to intrinsic compensatory mechanisms. Post-mortem
analyses of nigrostriatal integrity demonstrated that nigrostriatal
Figure 6. Post-mortem confirmation of in vivo MRI signal changes. (A) Cavalieri estimator probe measurement of corpus striatum volume
post-mortem in saline and lactacystin-injected animals reveals a significant decrease in the volume of the ipsilateral striatum in lesioned animals,
(***p,0.01). (B) Linear regression analysis reveals a strong correlation between measurement of striatal volume in both groups from either MRI or
post-mortem histology (r=. 879). (C) Cortical thickness measurements post-mortem confirms cortical thinning in the M1 and S1BF cortices of
lactacystin-lesioned animals but not saline controls, consistent with MRI data. (*p,0.05; **p,0.01). (D) Linear regression also reveals a robust
correlation between cortical thickness measurements in the M1 and S1BF by MRI or from post-mortem histological sections (r=. 646 and .691;
respectively). Data shown in (A) and (C) are mean volume or thickness, respectively, 6 SEM. Saline, N=5, lactacystin, N=7.
doi:10.1371/journal.pone.0017269.g006
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no further increase at 3 or 5 wks. Overall, these data are consistent
with an acute, rapid degeneration of nigral DA neurons and striatal
DA deafferentation at this dose of lactacystin (10 mg), characteristic
of the static non-progressive lesions generated following L-MFB
administration of neurotoxins [49,50].
As such, structural brain changes at wk 1 post-lesion may be the
most relevant in this model. This time-point reflects end-stage PD,
where nigrostriatal destruction is almost complete [51]. At wk 1, in
vivo significant tissue volume changes were located only in the
cortex, including thinning of the M1 and the S1BF cortex, which
was confirmed post-mortem. Cortical thinning may therefore
Figure 8. Qualitative analysis of neuronal loss in extra-nigral brain regions demonstrating MRI changes at week 5 post-lesion. (A)
Lactacystin microinjection does not result in gross neuronal loss in the ipsilateral primary motor (M1) cortex. By contrast, compared to saline controls
widespread neuronal loss is apparent (solid black arrows) in (B) ipsilateral ventral thalamic nuclei, (C) ipsilateral ventral midbrain extra-nigral nuclei
and (D) substantia nigra pars compacta (SNc) in lesioned animals. Note the loss of neurons in the ventral tegmental area (VTA) and substantia nigra
pars reticulata (SNr). All images64 magnification, scale bar=200 mm. Abbreviations: M1, primary motor cortex; cg, cingulum; cc, corpus callosum; ic,
internal capsule; vpl, ventral posterolateral thalamic nucleus; vpm, ventral posteromedial thalamic nucleus; mgn, medial geniculate nucleus; APTN,
anterior pretectal nucleus; PaR, pararubral nucleus; RN, red nucleus. Saline, N=5, lactacystin, N=7.
doi:10.1371/journal.pone.0017269.g008
Figure 7. Neuropathological alterations following lactacystin lesioning of the nigrostriatal system. (A) Lactacystin microinjection
induces substantial TH+ fibre loss in the ipsilateral striatum, accompanied by ventricular enlargement (*). (B) Quantification of TH
+ fibre density in
lesioned (N=7) and control animals (N=5). Data shown are mean TH fibre density (A.U) 6 SEM; ***p,0.001; ipsilateral vs. contralateral hemisphere.
(C) Striatal volume change in lesioned animals is not associated with gross neuronal loss confirmed by (D) optical fractionator counts of striatal
neuron number. Data shown are the mean number NeuN+ cells 6 SEM; ***p,0.001; ipsilateral vs. contralateral hemisphere. (E, F) Lactacystin
microinjection induces significant loss of nigral TH+ cell bodies. Data shown are mean number TH+ cells in the SNc 6 SEM. ***p,0.001; ipsilateral vs.
contralateral hemisphere. (G) Loss of TH+ cells is accompanied by formation of a-synuclein immunopositive aggregates in lesioned animals compared
to saline controls. Note the clear pattern and distribution of a-synuclein inclusions, with some surviving TH+ cells showing inclusion pathology (solid
white arrows), some surviving TH+ cells without a-synuclein positive inclusions (dashed white arrows), TH-negative cells with a-synuclein positive
inclusions (yellow solid arrows) and aggregates of a-synuclein in the brain parenchyma (asterisks). Images in (A, C, E) 64 magnification, scale
bar=200mm, images in (G) 640 magnification, scale bar=20 mm.
doi:10.1371/journal.pone.0017269.g007
Extra-Nigral Damage Predicts Behavioural Deficits
PLoS ONE | www.plosone.org 12 February 2011 | Volume 6 | Issue 2 | e17269reflect the primary neuroanatomical alteration related to loss of
nigral dopaminergic neurons in this model. Interestingly, these
data are consistent with clinical MRI studies, reporting cortical
volume changes in both early [52,53,54] and late-stage PD
patients [55,56,57], although in later stages this is heavily
influenced by co-morbidity with dementia [55,58]. Cortical
thinning is however, also present in non-demented late-stage PD
patients [55,58,59,60]. Importantly, however, imaging data from
acute time-points post-lesion are required to confirm the timing of
onset of cortical thinning in relation to nigral dopaminergic
neuronal loss. Notably, we also did not detect any change in the
volume of the hippocampal formation in lesioned animals, by
manual segmentation. Several clinical imaging studies have
identified decreased grey matter density in the hippocampus
associated with depression and cognitive impairment in PD and
Parkinson’s disease dementia (PDD) patients [61,62,63]. This may
be explained by the low sensitivity of the manual segmentation
approach to detect subtle volume change. However, the more
sensitive DBM method also did not detect hippocampal volume
change. Thus, it may be that our model simply does not
recapitulate the neuropathology associated with hippocampal
volume change in PD. However, this study did have a small
number of subjects, thus lowering statistical power to detect
volume changes. Replication in a larger cohort with DBM analysis
may identify hippocampal volume loss.
By contrast to wk 1, structural brain changes at wks 3 and 5
post-lesion are likely to reflect secondary neurodegeneration
resulting from the initial insult in this model. Longitudinal MRI
is therefore able to detect and chart the sequence of primary and
secondary neuroanatomical changes caused by nigral neurode-
generation, which can be used to predict behavioural impair-
ments.
Predictive power of neuroanatomical changes detected
by MRI
Linear multiple regression and correlation analyses reveal
several important findings regarding the predictive power of brain
volume changes in lesioned animals. Notably, decreased cortical
volume was the best predictor of grip strength and rotarod
performance, consistent with the notion that cortical changes are
most likely linked to primary nigrostriatal degeneration. Interest-
ingly, functional changes in cortical structures, including the
anterior cingulate, motor and somatosensory cortex is associated
with PD motor symptoms as evidenced by several functional MRI
(fMRI)-based studies in the clinic [64,65,66,67,68] and in animal
models [13,14,69,70]. Unexpectedly, lateral ventricle (LV) volume
best predicted the degree of apomorphine rotation. Although LV
hypertrophy is reported in and correlates with clinical symptoms
in PD patients [6], this is of little intrinsic value, since it is a
measure of global, non-specific changes in brain structure.
Overall, whilst these results do not imply an insignificant role of
basal ganglia structures in PD-related motor behavioural impair-
ment, they do suggest that subtle structural alterations in cortical
regions may play a role in PD motor deficits.
However, in disagreement with clinical findings [3,71], changes
in nigral T2 SI are not linked to behavioural dysfunction in this
model. However, this may be explained by the mismatching of
rapidly developing neuronal death due to proteasome inhibition,
versus the relatively delayed accumulation of iron in the SN in this
model, which potentially underlies the hyperintense contrast in the
SN [11,23,24,25].
Neurobiology underlying neuroanatomical changes
Whilst correlation analyses support the notion that cortical
volume changes are related to motor dysfunction in this model,
post-mortem validation of MRI signal changes is crucial before
these can be accepted as surrogate markers. The excellent
correspondence between in vivo MRI and post-mortem measure-
ment of cortical thinning indicates that this measure may be a
useful surrogate marker of motor impairment.
Establishing the mechanisms that underlie these changes remains
however a challenge. Interestingly, cortical thinning in lesioned
animals was not associated with gross neuronal loss at post-mortem.
These data are consistent with the observation that cortical thinning
may occur without neuronal loss in healthy elderly patients [72] and
thelack ofneuronal lossinthe neocortex of cognitively impaired PD
patients [73]. Notably, in this animal model STR volume changes in
Table 3. Correlations between post-mortem measures of
nigrostriatal damage and in vivo MRI measurements at wk 5.
Histology
MRI TH+ cells SNc TH+ fibres STR
VM volume .839** .884**
STR volume .749** .835**
CTX volume .840** .882**
LV volume 2.676* 2.771**
M1 thickness .751** .841**
S1BF thickness .494 .574
SN T2 SI .576 .602
*Correlation is significant at the 0.05 level,
**correlation is significant at the 0.01 level. (Abbreviations: VM, ventral midbrain;
STR, corpus striatum; CTX, cortex; LV, lateral ventricle; M1, primary motor cortex,
S1BF, primary somatosensory cortex barrel field; SN, substantia nigra; SI, signal
intensity).
doi:10.1371/journal.pone.0017269.t003
Table 4. Multiple regression analysis between MRI and post-
mortem histology data.
Post-mortem histology Equation model predicting histology at Wk 5
TH+ cells SNc =233198.18+(.829*CTX volume)
TH+ fibres STR =2132.03+(.947*VM volume)
(Abbreviations: CTX, cortex; VM, ventral midbrain; SNc, substantia nigra pars
compacta; STR, corpus striatum.)
doi:10.1371/journal.pone.0017269.t004
Table 5. Correlation analysis between post-mortem histology
and behaviour.
Behaviour
Histology GSM test
Accelerating
rotarod
Apomorphine
rotation
TH+ cells SNc .839** .749** .840**
TH+ fibres CPu .884** .835** .882**
*Correlation is significant at the 0.05 level,
**correlation is significant at the 0.01 level. Abbreviations: SNc, substantia nigra
pars compacta; STR, corpus striatum.
doi:10.1371/journal.pone.0017269.t005
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consistent with findings in PD patients and other animal models
[74,75,76]. Volume changes in the CTX and STR in this model
may therefore be a consequence of the loss of DA innervation from
the midbrain [47,75,76,77]. Indeed, cortical DA depletion due to
loss of mesocortical inputs results in dendritic spine remodeling [77]
and altered synaptic morphology [78] in layer V cortical projection
neurons, consistent with a functional re-organisation of these
structures following lossof DA inputs from the midbrain.Potentially
however, tissue volume changes in the CTX and STR may also
reflect glial cell pathology. Indeed, whilst there are extensive studies
on neurons, little attention has been paid to the effect of proteasome
inhibition in glial cells, in particular, astrocytes. Notably, lactacystin
has been reported to induce dose-dependent decreases in both
proliferation and induces morphological changes in cultured
cortical astrocytes [29,30].
Post-mortem analysis revealed however, gross neuronal loss in
the ventral midbrain and thalamus by 3 wks post-lesion, but not
prior to this, consistent with the onset of volumetric change in
these structures detected by MRI. Thus, volume change in these
structures may reflect trans-synaptic neuronal loss, consistent with
previous observations in lactacystin-lesioned animals [79]. How-
ever, a role for concomitant glial cell pathology cannot be
excluded. Alternatively, thalamic neuronal loss may reflect a
consequence of functional changes in basal ganglia circuitry due to
DA depletion [80,81,82]. Consistent with this notion, thalamic
neurodegeneration has been identified in post-mortem PD brain
tissue [83,84,85,86] and PD animal models [80,87].
Crucially however, whilst dopaminergic neurons may be
preferentially sensitive to proteasome inhibition [26] evidence
suggests that synthetic proteasome inhibitors induce dose-depen-
dent dopaminergic neuronal degeneration and are associated with a
significant risk of non-specific neuronal and/or glial cell toxicity at
higher doses [11,22,23,27]. Thus, whilst the MRI changes observed
in the current study are clearly linked to DA depletion, we cannot
exclude the possibility that these may also reflect additional loss of
other vulnerable neuronal or glial cell populations. A more
progressive nigrostriatal degeneration, as reported with lower doses
of lactacystin [23], may therefore provide more clinically-relevant
correlations between behavioural deficits and MRI changes.
Additionally, it is not clear if tissue volume and pathological
changes in extra nigral regions are accompanied by pathological a-
synuclein deposition in this model. Consequently, future studies
examining both the dose-dependence of lactacystin-induced brain
volumetric changes and further detailed post-mortem histological
studies are required to fully understand the neuropathological
correlates of brain volume changes in this model.
Conclusions
Manual and voxel-based MRI analysis methods revealed that
microinjection of lactacystin into the L-MFB results in a distinct
sequale of structural alterations in the brain, many of which are
consistent with descriptions of structural alterations in PD patients.
Of these, cortical thinning exhibited a greater predictive power for
the degree of functional impairment compared to all other in vivo
measures. Structural changes in other brain regions may reflect
secondary neuropathology due to non-specific toxicity of lactacys-
tin or are the consequence of a functional reorganisation of basal
ganglia circuitry following DA depletion. Consequently, these
changes do not predict motor impairment in vivo. However,
confirmation of these finding in a larger cohort of animals, at
lower doses of lactacystin and in other pre-clinical models of PD,
such as the rat 6-hydroxydopamine (6-OHDA) or 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) murine and non-hu-
man primate models will be important and significant advances.
Nonetheless, these data highlight the importance of a compre-
hensive anatomical assessment beyond the primary insult in the
nigrostriatal system. Furthermore, these data demonstrate that
integration of MRI data with post-mortem neuropathology is not
only essential to confirm the relevance of in vivo MRI findings to
behavioural dysfunction. Moreover, this integrative approach
provides a powerful model system with which to investigate the
neuropathological correlates of structural MRI changes as
observed in the brains of PD patients.
Supporting Information
Figure S1 Neurological scoring of animal health reveals
lactacystin-lesioned (N=7) animals develop a progres-
sive increase in neurological score, consistent with
subtle motor deficits and behavioural abnormalities.
Neurological scores increase to day 14 post-lesion and then
become static. Saline controls (N=5) display no gross neurological
abnormalities.
(TIF)
Figure S2 Longitudinal in vivo MRI detects a reduction
in whole brain, but not cerebellum volume in lactacys-
tin-lesioned animals (N=7) compared to saline controls
(N=5). Data shown are mean volume 6 standard error.
*p,0.05; saline vs. lactacystin.
(TIF)
Figure S3 Time-course of nigrostriatal pathology in-
duced by lactacystin microinjection into the L-MFB. (A)
Lactacystin microinjection induces substantial TH+ fibre loss in
the ipsilateral striatum, accompanied by ventricular enlargement.
(B) Quantification of TH
+ fibre density in lesioned (N=5) and
control animals (N=5) reveals this is maximal by week 1 post-
lesion and does not progress further. Data shown are mean TH
fibre density (A.U) 6 SEM; ***p,0.001. (C, D) Quantification of
nigral TH+ cell bodies in lesioned and control animals reveals this
Table 6. Multiple regression analysis between post-mortem histology and in vivo MRI with behavioural data.
Equation models predicting behaviour
Behaviour In vivo MRI volumes Post-mortem histology MRI and Histology
Grip Strength =2921.627+(0.9146CTX) =30.986+(0.9306Fibre Density) =24.759+(0.9416Fibre density)
Rotarod =2539.377+(0.8266M1) =69.408+(0.6946Fibre Density) =539.377+(0.8266M1)
Rotameter =256.655+(0.8466LV) =477.563+(20.9266Fibre Density) =586.086+(20.9556Fibre Density)
(Abbreviations: CTX, cortex; M1, primary motor cortex, LV, lateral ventricles.)
doi:10.1371/journal.pone.0017269.t006
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Data shown are mean number TH+ cells in the SNc 6 standard
error ***p,0.001. (E) Loss of TH+ cells is accompanied by
formation of a-synuclein immunopositive aggregates in lesioned
animals compared to saline controls at week 1 and 3. Note the
clear pattern and distribution of a-synuclein inclusions, with some
surviving TH+ cells showing inclusion pathology (solid white
arrows), some surviving TH+ cells without a-synuclein positive
inclusions (dashed white arrows), TH-negative cells with a-
synuclein positive inclusions (yellow solid arrows) and aggregates
of a-synuclein in the brain parenchyma (asterisks). Images in (A, C,
E) 64 magnification, scale bar=200mm, images in (G) 640
magnification, scale bar=20 mm.
(TIF)
Figure S4 Qualitative analysis of neuronal loss in extra-
nigral brain regions demonstrating MRI changes at
week 1 post-lesion. (A) Lactacystin microinjection (N=5) does
not result in apparent neuronal loss in the ipsilateral primary
motor (M1) cortex at this time-point. Similarly, compared to saline
controls (N=5) no neuronal loss is evident in (B) ipsilateral ventral
thalamic nuclei, (C) ipsilateral ventral midbrain extra-nigral nuclei.
By contrast, substantial neuronal loss is present in (D) the
substantia nigra pars compacta (SNc). Note also the loss of
neurons in the nearby ventral tegmental area (VTA) and
substantia nigra pars reticulata (SNr). All images 64 magnifica-
tion, scale bar=200 mm. Abbreviations: M1, primary motor
cortex; cg, cingulum; cc, corpus callosum; ic, internal capsule; vpl,
ventral posterolateral thalamic nucleus; vpm, ventral posterome-
dial thalamic nucleus; mgn, medial geniculate nucleus; APTN,
anterior pretectal nucleus; PaR, pararubral nucleus; RN, red
nucleus.
(TIF)
Figure S5 Qualitative analysis of neuronal loss in extra-
nigral brain regions demonstrating MRI changes at
week 3 post-lesion. (A) Lactacystin microinjection (N=5) does
not result in apparent neuronal loss in the ipsilateral primary
motor (M1) cortex at this time-point. By contrast, compared to
saline controls (N=5) widespread neuronal loss is already apparent
(solid black arrows) in (B) ipsilateral ventral thalamic nuclei, (C)
ipsilateral ventral midbrain extra-nigral nuclei and (D) substantia
nigra pars compacta (SNc). Note also the loss of neurons in the
nearby ventral tegmental area (VTA) and substantia nigra pars
reticulata (SNr). All images64 magnification, scale bar=200 mm.
Abbreviations: M1, primary motor cortex; cg, cingulum; cc,
corpus callosum; ic, internal capsule; vpl, ventral posterolateral
thalamic nucleus; vpm, ventral posteromedial thalamic nucleus;
mgn, medial geniculate nucleus; APTN, anterior pretectal nucleus;
PaR, pararubral nucleus; RN, red nucleus.
(TIF)
Table S1 Summary of overall statistical results from repeated
measures 2-way ANOVA for in vivo serial MRI measurements.
(DOC)
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